The Disruptive Technologies Innovation Fund, a major driver of Impact 2030 research and innovation strategy, has awarded Amara Therapeutics funding for RiSolve - a safe and effective personalised therapy that will disrupt the overactive bladder treatment market using an innovative artificial intelligence-based digital platform.
Read the Departmental Press Release
Read more on Silicon Republic
Amara Therapeutics were encouraged as on of the runner-up finalists in this years EIT Health Catapult. Health Catapult is a unique competition and training programme which showcases biotech, medtech and digital health start-ups to leading experts and investors across Europe.
Big ideas is an Enterprise Ireland led event that empowers the front runners in Irish research, to take centre stage and pitch their technology solutions and business propositions to an audience comprised of the Irish research and investment communities. Big Ideas provides investor ready start-ups with a bespoke pathway to success, support with growing their business and creating jobs in Ireland.
A Galway-headquartered medical technology company is aiming to raise €3 million by the end of the year, as part of a plan to commercialise a new product it believes can vastly improve treatment options for those who have overactive bladder (OAB) problems.